S&P 500   4,532.85 (+0.29%)
DOW   35,581.61 (+0.35%)
QQQ   374.86 (-0.16%)
AAPL   148.94 (+0.12%)
MSFT   307.59 (-0.21%)
FB   340.84 (+0.25%)
GOOGL   2,838.17 (-0.93%)
TSLA   865.34 (+0.12%)
AMZN   3,420.04 (-0.70%)
NVDA   220.68 (-1.00%)
BABA   177.34 (+0.19%)
NIO   39.66 (-0.92%)
CGC   14.15 (-1.32%)
GE   105.63 (+0.86%)
AMD   116.26 (-0.06%)
MU   68.49 (+1.36%)
T   25.94 (+1.37%)
F   15.96 (+3.50%)
ACB   7.56 (+1.48%)
DIS   170.64 (-0.32%)
PFE   42.74 (+1.54%)
BA   216.13 (+0.07%)
AMC   40.94 (+0.34%)
S&P 500   4,532.85 (+0.29%)
DOW   35,581.61 (+0.35%)
QQQ   374.86 (-0.16%)
AAPL   148.94 (+0.12%)
MSFT   307.59 (-0.21%)
FB   340.84 (+0.25%)
GOOGL   2,838.17 (-0.93%)
TSLA   865.34 (+0.12%)
AMZN   3,420.04 (-0.70%)
NVDA   220.68 (-1.00%)
BABA   177.34 (+0.19%)
NIO   39.66 (-0.92%)
CGC   14.15 (-1.32%)
GE   105.63 (+0.86%)
AMD   116.26 (-0.06%)
MU   68.49 (+1.36%)
T   25.94 (+1.37%)
F   15.96 (+3.50%)
ACB   7.56 (+1.48%)
DIS   170.64 (-0.32%)
PFE   42.74 (+1.54%)
BA   216.13 (+0.07%)
AMC   40.94 (+0.34%)
S&P 500   4,532.85 (+0.29%)
DOW   35,581.61 (+0.35%)
QQQ   374.86 (-0.16%)
AAPL   148.94 (+0.12%)
MSFT   307.59 (-0.21%)
FB   340.84 (+0.25%)
GOOGL   2,838.17 (-0.93%)
TSLA   865.34 (+0.12%)
AMZN   3,420.04 (-0.70%)
NVDA   220.68 (-1.00%)
BABA   177.34 (+0.19%)
NIO   39.66 (-0.92%)
CGC   14.15 (-1.32%)
GE   105.63 (+0.86%)
AMD   116.26 (-0.06%)
MU   68.49 (+1.36%)
T   25.94 (+1.37%)
F   15.96 (+3.50%)
ACB   7.56 (+1.48%)
DIS   170.64 (-0.32%)
PFE   42.74 (+1.54%)
BA   216.13 (+0.07%)
AMC   40.94 (+0.34%)
S&P 500   4,532.85 (+0.29%)
DOW   35,581.61 (+0.35%)
QQQ   374.86 (-0.16%)
AAPL   148.94 (+0.12%)
MSFT   307.59 (-0.21%)
FB   340.84 (+0.25%)
GOOGL   2,838.17 (-0.93%)
TSLA   865.34 (+0.12%)
AMZN   3,420.04 (-0.70%)
NVDA   220.68 (-1.00%)
BABA   177.34 (+0.19%)
NIO   39.66 (-0.92%)
CGC   14.15 (-1.32%)
GE   105.63 (+0.86%)
AMD   116.26 (-0.06%)
MU   68.49 (+1.36%)
T   25.94 (+1.37%)
F   15.96 (+3.50%)
ACB   7.56 (+1.48%)
DIS   170.64 (-0.32%)
PFE   42.74 (+1.54%)
BA   216.13 (+0.07%)
AMC   40.94 (+0.34%)
NASDAQ:INBX

Inhibrx News Headlines

$38.09
-1.82 (-4.56 %)
(As of 10/20/2021 03:21 PM ET)
Add
Compare
Today's Range
$37.86
$40.10
50-Day Range
$26.75
$40.00
52-Week Range
$14.27
$50.97
Volume5,134 shs
Average Volume176,092 shs
Market Capitalization$1.44 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.26

Media Mentions By Week

Inhibrx Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

INBX
News Sentiment

0.98

0.38

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

INBX Articles
This Week

0

0

INBX Articles
Average Week

Get Inhibrx News Delivered to You Automatically

Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter.

Inhibrx (NASDAQ INBX) News Headlines Today

SourceHeadline
marketbeat.com logoInhibrx's (INBX) Buy Rating Reaffirmed at JMP Securities
marketbeat.com - October 13 at 12:32 PM
MarketBeat logoInhibrx (NASDAQ:INBX) Shares Up 6.7%
americanbankingnews.com - October 13 at 1:46 PM
MarketBeat logoInhibrx (NASDAQ:INBX) Stock Rating Reaffirmed by JMP Securities
americanbankingnews.com - October 13 at 12:26 PM
finance.yahoo.com logo30 Stocks Moving In Tuesday's Mid-Day Session
finance.yahoo.com - October 12 at 5:34 PM
finance.yahoo.com logoINBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing
finance.yahoo.com - October 12 at 12:32 PM
finance.yahoo.com logoHere's Why Inhibrx Stock Is on the Move Today
finance.yahoo.com - October 12 at 12:32 PM
MarketBeat logoInhibrx (NASDAQ:INBX) Shares Gap Up to $27.61
americanbankingnews.com - October 12 at 10:52 AM
MarketBeat logoInhibrx (NASDAQ:INBX) Shares Gap Up to $31.14
americanbankingnews.com - October 5 at 12:22 PM
MarketBeat logoInhibrx (NASDAQ:INBX) Shares Gap Down to $36.77
americanbankingnews.com - September 28 at 11:14 AM
barrons.com logoInhibrx Inc.
barrons.com - August 26 at 9:37 PM
finance.yahoo.com logoThe Inhibrx, Inc. (NASDAQ:INBX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
finance.yahoo.com - August 12 at 3:57 PM
finance.yahoo.com logoInhibrx Reports Second Quarter 2021 Financial Results
finance.yahoo.com - August 9 at 6:45 PM
markets.businessinsider.com logoInhibrx Launches Mid-Stage Bone Cancer Study With INBRX-109, Amends Loan Agreement With Oxford
markets.businessinsider.com - June 22 at 8:08 AM
msn.com logoBRIEF-Inhibrx Initiates Potential Registration-Enabling Phase 2 Study Of Inbrx-109
msn.com - June 21 at 7:36 PM
finance.yahoo.com logoInhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford
finance.yahoo.com - June 21 at 7:36 PM
finance.yahoo.com logoInhibrx Announces Participation in Upcoming Investor Conferences
finance.yahoo.com - May 17 at 7:25 PM
nasdaq.com logoEarnings Update: Inhibrx, Inc. (NASDAQ:INBX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
nasdaq.com - May 16 at 1:43 PM
finance.yahoo.com logoInhibrx Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 13 at 11:01 PM
finance.yahoo.com logoInhibrx Surpasses 4Q Revenue Estimates; Street Remains Bullish
finance.yahoo.com - March 14 at 9:13 AM
markets.businessinsider.com logoInhibrx's INBRX-105 Shows Dose-Limiting Toxicities In Early-Stage Solid Tumors Study
markets.businessinsider.com - March 12 at 9:12 PM
finance.yahoo.com logoInhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist
finance.yahoo.com - March 12 at 9:12 PM
finance.yahoo.com logoInhibrx Announces Participation in Upcoming Investor Conference
finance.yahoo.com - February 1 at 10:40 PM
finance.yahoo.com logoInhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients
finance.yahoo.com - January 13 at 10:13 AM
reuters.com logoInhibrx Inc
reuters.com - December 22 at 10:58 PM
finance.yahoo.com logoIs INBX A Good Stock To Buy Now?
finance.yahoo.com - December 10 at 6:37 PM
nasdaq.com logoIndustry Analysts Just Made A Dazzling Upgrade To Their Inhibrx, Inc. (NASDAQ:INBX) Revenue Forecasts
nasdaq.com - November 22 at 12:48 PM
finance.yahoo.com logoInhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford
finance.yahoo.com - November 13 at 6:21 PM
seekingalpha.com logoInhibrx's INBRX-109 shows encouraging benefit in bone cancer
seekingalpha.com - November 12 at 2:46 PM
msn.com logoThe Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal
msn.com - November 12 at 8:46 AM
seekingalpha.com logoInhibrx's INBRX- 109 shows encouraging benefit in bone cancer
seekingalpha.com - November 12 at 8:46 AM
finance.yahoo.com logoInhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients
finance.yahoo.com - November 11 at 5:34 PM
finance.yahoo.com logoInhibrx Announces Participation in Upcoming Investor and Scientific Conferences
finance.yahoo.com - November 5 at 5:01 PM
finance.yahoo.com logoInhibrx, Inc. (INBX)
finance.yahoo.com - October 19 at 11:48 PM
finance.yahoo.com logoInhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - August 31 at 6:14 PM
finance.yahoo.com logoOxford Finance Announces $10 Million Credit Facility with Inhibrx, Inc.
finance.yahoo.com - August 31 at 6:14 PM
Get Inhibrx News Delivered to You Automatically

Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 10/20/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.